Helus Pharma Inc. Common Stock
HELP
61 hedge funds and large institutions have $8.22M invested in Helus Pharma Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 14 closing their positions.
2% more funds holding
Funds holding: 60 → 61 (+1)
1.13% more ownership
Funds ownership: 9% → 10.13% (+1.1%)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more capital invested
Capital invested by funds: $8.19M → $8.22M (+$34.2K)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.87M |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$279K |
| 3 |
CF
Cantor Fitzgerald
New York
|
+$214K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$70.3K |
| 5 |
Cerity Partners
New York
|
+$42.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$236K |
| 2 |
PCM
Penserra Capital Management
Orinda,
California
|
-$209K |
| 3 |
PCC
Perry Creek Capital
New York
|
-$199K |
| 4 |
BlackRock
New York
|
-$148K |
| 5 |
O
OrbiMed
New York
|
-$50.4K |
HELP Hedge Fund Activity: Q3 2022 in Review
61 of the 5,830 institutional investors tracked by Wall St. Rank reported a position in Helus Pharma Inc. Common Stock (HELP) for Q3 2022, worth a combined $8.22M — up 0.42% from $8.19M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new HELP positions and 14 closed out — a net gain of 1 holder — while 9 added to existing stakes and 11 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.87M. The largest seller was Barclays, exiting entirely with an estimated $236K sold.
- 61 institutional investors held Helus Pharma Inc. Common Stock (HELP) as of Q3 2022, up from 60 in Q2 2022.
- Funds reported $8.22M of Helus Pharma Inc. Common Stock stock for Q3 2022, up 0.42% quarter-over-quarter.
- 15 funds opened new Helus Pharma Inc. Common Stock positions in Q3 2022 and 14 closed out, a net change of +1 holder.
- The largest Helus Pharma Inc. Common Stock buyer in Q3 2022 was Morgan Stanley, an estimated $1.87M added.
- The largest Helus Pharma Inc. Common Stock seller in Q3 2022 was Barclays, an estimated $236K sold.
Based on aggregated 13F filings for Q3 2022.